The stock's fall snapped a five-day winning streak.

Hypertension Diagnostics (OTCMKTS:HDII – Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will ...

This was the stock's fifth consecutive day of gains.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report)‘s stock had its “market outperform” rating restated by JMP Securities ...

The average one-year price target for Inovio Pharmaceuticals (NasdaqCM:INO) has been revised to 19.21 / share. This is an increase of 2,590.47% from the prior estimate of 0.71 dated January 16, 2024.

Inovio Pharmaceuticals shares are trading lower by 40% during Friday's session. The company priced a public offering of 10 million shares of common stock and accompanying warrants. Inovio ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of ...

Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the fourth quarter of 2023. Inovio Pharmaceuticals reported earnings per share of -$1.10. This was above the analyst estimate for EPS ...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.

PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV ...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.